We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Long-Term Survival in Repaired TOF is Excellent

By HospiMedica International staff writers
Posted on 14 Jan 2019
A new study shows that the 25-year survival rate of surgical tetralogy of Fallot (TOF) patients is primarily influenced by the coexistence of an associated genetic condition.

Researchers at Emory University (Atlanta, GA, USA), the University of Minnesota (UMN; Minneapolis, USA), and other institutions conducted a retrospective cohort study involving 3,283 patients (56.4% men) enrolled in the Pediatric Cardiac Care Consortium (PCCC) between 1982 and 2003 and whom survived surgical repair of simple TOF. More...
Main outcomes and measures were transplant-free survival during the early (less than six years) and late phase following surgical repair, adjusted for era and patient characteristics.

The results revealed that one-year survival rate following TOF repair was 98.6%, decreasing to 97.8% at five years; 97.1% at 10 years; 95.5% at 20 years; and 94.5% at 25 years, with an early steep mortality hazard increase peaking shortly after repair, followed by a late, gradual hazard increase. Increased mortality risks were found in non-valve-sparing operations and staged repair. Genetic abnormalities were associated with increased mortality risk in both early and late post-surgical phases. The study was published on December 19, 2018, in JAMA Cardiology.

“Long-term transplant-free survival beyond the first six years is influenced primarily by the coexistence of an associated genetic condition. Within the 25-year follow-up period, most deaths were associated with the underlying diagnosis of TOF and mediated by arrhythmias and congestive heart failure,” concluded lead author Clayton Smith, MD, of Emory University, and colleagues. “Staged repair and non–valve-sparing operations were negatively associated with survival in the early post-repair phase. These data are important for patients with repaired TOF and their caretakers, and may guide surgical strategies for optimizing the long-term outcomes of this population.”

TOF is a cyanotic congenital heart disease characterized by four main findings; pulmonary stenosis, a narrowing of the exit from the right ventricle; a ventricular septal defect; right ventricular hypertrophy; and an overriding aorta, which allows blood from both ventricles to enter the aorta. Symptoms include episodes of bluish color to the skin. Other symptoms may include a heart murmur, finger clubbing, and easy tiring upon breastfeeding. The cause is typically not known.

Related Links:
Emory University
University of Minnesota


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Immobilization System
Cranial 4Pi Immobilization
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Annotation platform for pixel-level labeling of free-text findings in 3D chest CT. (Baharoon M, Luo L, Moritz M, et al. ReXGroundingCT: A 3D chest CT dataset for segmentation of findings from free-text reports. NEJM AI. 2026;3(7). doi:10.1056/AIdbp2501220.)

Public Chest CT Dataset Supports Explainable AI in Diagnostic Radiology

Chest computed tomography scans generate complex three-dimensional images that can be difficult for artificial intelligence systems to explain clearly. Clinicians need to verify AI findings before using... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.